Copertina

Emerging tools for the early detection of prostate cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Muhammad Haider, Jeffrey J. Leow, Tobias Nordström, Ashkan Mortezavi, Peter Albers, Rakesh Heer, Prabhakar Rajan
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	BJUI Compass
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Sociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London
di: Muhammad Haider, et al.
Pubblicazione: (2025)

Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
di: Arjun Pon Avudaiappan, et al.
Pubblicazione: (2024)

AI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
di: Muhammad Imran, et al.
Pubblicazione: (2026)

Understanding symptom contribution to sex inequality in bladder and renal cancer stage at diagnosis
di: Yin Zhou, et al.
Pubblicazione: (2024)

Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
di: Eric V. Li, et al.
Pubblicazione: (2024)

Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer
di: Austin Drysch, et al.
Pubblicazione: (2025)

Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
di: Esther H. J. Hamoen, et al.
Pubblicazione: (2025)

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
di: Eric Margolis, et al.
Pubblicazione: (2025)

Incorporating the NICE Cambridge Prognostic Groups and Predict Prostate into a structured informed‐decision making clinic reduces over‐treatment rates of early prostate cancer
di: Vincent J. Gnanapragasam, et al.
Pubblicazione: (2025)

Incidental crossed fused renal ectopia detected during prostate cancer staging: A photorealistic three‐dimensional rendering
di: Kei Ushijima, et al.
Pubblicazione: (2025)

Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
di: Sophia M. Abusamra, et al.
Pubblicazione: (2025)

A machine learning algorithm for automatic tumour board recommendations in prostate cancer patients
di: Marcus Sondermann, et al.
Pubblicazione: (2025)

Micro‐ultrasound tissue echogenicity predicts prostate cancer grade
di: Ailene E. Corona, et al.
Pubblicazione: (2026)

Evaluating the utility of the HAS‐BLED bleeding‐estimator tool for transurethral resection of prostate
di: Lu Yu Kuo, et al.
Pubblicazione: (2025)

Bibliometric analysis of focal therapy in prostate cancer research
di: Mohammed Shahait, et al.
Pubblicazione: (2024)

Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer
di: Ruth Pidsley, et al.
Pubblicazione: (2024)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
di: Jennifer Dunsmore, et al.
Pubblicazione: (2024)

Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
di: Abel Tesfai, et al.
Pubblicazione: (2024)

Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom
di: Nadia Rokan, et al.
Pubblicazione: (2025)

National survey of urologists' views on prostate cancer screening in the United Kingdom
di: Nikhil Mayor, et al.
Pubblicazione: (2026)

‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
di: Ryan Sutherland, et al.
Pubblicazione: (2024)

The significant costs of prostate cancer management—An analysis from a Caribbean hospital
di: Geneva Pantoja, et al.
Pubblicazione: (2025)

Impact of recreational football in men with prostate cancer undergoing androgen deprivation therapy
di: Sofia Mesquita, et al.
Pubblicazione: (2025)

Association between beta‐blocker atenolol use and prostate cancer upgrading in active surveillance1
di: Ali H. Zahalka, et al.
Pubblicazione: (2024)

Real‐world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience
di: Samantha Shekar, et al.
Pubblicazione: (2025)

Potential gains from radical treatment of men with prostate cancer according to life expectancy
di: Sandra Irenaeus, et al.
Pubblicazione: (2025)

MRI performance to identify clinically significant prostate cancer following focal cryo‐ablation
di: Herbert Lepor, et al.
Pubblicazione: (2025)

Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review
di: Jonathon Dawson, et al.
Pubblicazione: (2024)

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
di: Alan Priester, et al.
Pubblicazione: (2024)

Perioperative antibiotic prophylaxis, prostate size and transperineal prostate biopsy
di: Maxwell Louis Sandberg, et al.
Pubblicazione: (2026)

First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
di: See‐Tong Pang, et al.
Pubblicazione: (2025)

Clinical validation of a biopsy‐based six‐gene signature prognostic for aggressive prostate cancer
di: Agnieszka Krzyzanowska, et al.
Pubblicazione: (2024)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
di: Nicole Handa, et al.
Pubblicazione: (2025)

Exploring patient and clinician opinions, perspectives and acceptance of the use of artificial intelligence in the histological diagnosis of prostate cancer
di: Lisa Browning, et al.
Pubblicazione: (2025)

The impact of pre‐biopsy MRI and additional testing on prostate cancer screening outcomes: A rapid review
di: Abel Tesfai, et al.
Pubblicazione: (2024)

Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
di: Mohammadmehdi Adhami, et al.
Pubblicazione: (2026)

The potential role of precision medicine to alleviate racial disparities in prostate, bladder and renal urological cancer care
di: Kunal K. Sindhu, et al.
Pubblicazione: (2024)

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
di: Stijn M. van den Bosch, et al.
Pubblicazione: (2026)

Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
di: Yuki Teramoto, et al.
Pubblicazione: (2026)

A sustainable and expedited ‘One‐Stop’ prostate cancer diagnostic pathway to reduce environmental impact and enhance accessibility
di: Lorenzo Storino Ramacciotti, et al.
Pubblicazione: (2024)